Leptomycin
Names | |
---|---|
Preferred IUPAC name
(2E,5S,6R,7S,9R,10E,12E,15R,16Z,18E)-17-Ethyl-6-hydroxy-3,5,7,9,11,15-hexamethyl-19-[(2S,3S)-3-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid | |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
ECHA InfoCard
|
100.125.530 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C33H48O6 | |
Molar mass | 540.741 g·mol−1 |
Density | 1.072 g/mL |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Leptomycins are secondary metabolites produced by Streptomyces spp.
Leptomycin B (LMB) was originally discovered as a potent
antifungal compound. [1] Leptomycin B was found to cause cell elongation of the fission yeast Schizosaccharomyces pombe. Since then this elongation effect has been used for the bioassay of leptomycin. However, recent data shows that leptomycin causes G1 cell cycle arrest in mammalian cells and is a potent anti-tumor agent against murine experimental tumors in combination therapy.[2]
Leptomycin B has been shown to be a potent and specific nuclear export inhibitor in humansribonucleoproteins.[citation needed]
Leptomycin A (LPA) was discovered together with LMB. LMB is twice as potent as LPA.[clarification needed]
See also
References
External links
- leptomycin+B at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Original data copied with permission from Leptomycin B manufacturer product page (Fermentek)